Clinical trial

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-11-29

PhasePHASE3

Study timeline

Study start (actual)2021-11-29Date precision: day

Registry last updated2022-05-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Elevated Intraocular Pressureunresolved

Interventions

Latanoprost ophthalmic solution, 0.005%DRUG

TC-002 latanoprost ophthalmic solution, 0.005%DRUG

Sponsors & collaborators

TearClear Corplead sponsor

Mapped research locations

San AntonioTexas, United States2 HoustonTexas, United States1 ClevelandOhio, United States1 TampaFlorida, United States1 RochesterNew York, United States1 LouisvilleKentucky, United States1 MemphisTennessee, United States1 TorranceCalifornia, United States1 Newport BeachCalifornia, United States1 El PasoTexas, United States1 GlendaleCalifornia, United States1 Garden GroveCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05165290 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.